Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Dollar Tree, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Dollar Tree, Inc. trades at $127.65 (market cap $24.86B). The key difference: Dollar Tree, Inc. is far larger — about 2.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | DLTR | |
|---|---|---|
Market Cap | $9.39B | $24.86B |
Sector | Health | Health |
52-Week High | $356.25 | $141.21 |
52-Week Low | $241.71 | $85.04 |
Enterprise Value | $9.14B | $31.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Dollar Tree (DLTR) trades at $130.9, up 0.94% on the day, with a bullish technical outlook and strong profitability metrics including a 34.71% ROE. Recent quarters have consistently beaten EPS estimates, and the company announced a $2.5 billion share repurchase authorization in July 2026. Revenue for 2025 was $17.58 billion, though net income was negative due to a significant tax charge, with a rebound to profitability projected for 2026.
The stock presents a mixed outlook: analyst consensus is a 'Buy' with a $129.08 price target near the current price, supported by solid cash flow and margin improvements. Key risks include competitive pressures, tariff impacts on margins, and execution of the turnaround strategy amid consumer spending shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
